COMM domain containing 9Genealiases: C11orf55 · HSPC166 · LINC00610
Q-omics provides the consensus-scored COMMD9 profile across patient tissues and cancer cell-line models. COMMD9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, COMMD9 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, COMMD9 protein abundance shows 25,690 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, LIHC, and PDAC as cancer lineages where COMMD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COMMD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COMMD9 survival associations across molecular data types. COMMD9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COMMD9 RNA expression–survival associations across cancer types. High COMMD9 expression shows unfavorable associations in KICH, LIHC and LUSC, but favorable associations in CESC, KIRC and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for COMMD9 RNA expression.
This table summarizes COMMD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COMMD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COMMD9 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, HNSC, STAD and COAD. The LIHC box plot shows higher COMMD9 RNA expression in tumor versus normal tissue (log2 FC = +0.821, t-test p < 0.001).
This table shows molecular features associated with COMMD9 in patient tissues and cancer cell lines. In patient samples, COMMD9 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, COMMD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
